Use the Back button in your browser to see the other results of your search or to select another record.
Detailed Search Results
| Il-6 inhibitors and TNF inhibitors: impact on exercise-induced cardiac adaptations in patients with rheumatoid arthritis [with consumer summary] |
| Jonck S, Adamsen ML, Rasmussen IE, Lytzen AA, Lok M, Vonsild Lund MA, Dreyer L, Jorgensen PG, Vejlstrup N, Kober L, Christensen R, Jacobsen S, Pedersen BK, Ellingsgaard H, Hojgaard P, Berg RMG, Christensen RH |
| JACC: Basic to Translational Science 2025 May;10(5):551-563 |
| clinical trial |
| This trial has not yet been rated. |
|
Interleukin-6 inhibitors (IL-6i) are commonly used in patients with rheumatoid arthritis to reduce inflammation from chronically increased IL-6. IL-6 levels increase transiently following exercise, exerting numerous positive effects. This study examined if beneficial exercise-induced cardiac adaptations were attenuated in patients with rheumatoid arthritis in concomitant IL-6i treatment compared with tumor necrosis factor inhibitors. Compared with control, we found that the tumor necrosis factor inhibitor-treated group, but not the IL-6i group, had a significant increase in left ventricular mass following 12 weeks of supervised exercise. However, the interaction effect of treatment modalities on exercise-induced cardiac adaptations was insignificant. (Exercise-induced Cardiac Adaptions in Rheumatoid Arthritis Patients During IL-6versus TNF Antibody Therapy; NCT05215509).
|
The database was last updated on 6 July 2026 (this includes records added or amended since 1 June 2026). The next update is planned for 3 August 2026. The total number of records on the database is 69,450.